sirolimus and Neoplasm-Regression--Spontaneous

sirolimus has been researched along with Neoplasm-Regression--Spontaneous* in 2 studies

Other Studies

2 other study(ies) available for sirolimus and Neoplasm-Regression--Spontaneous

ArticleYear
Complete regression of cutaneous B-cell lymphoma in a renal transplant patient after conversion from cyclosporin to sirolimus.
    Transplantation proceedings, 2007, Volume: 39, Issue:4

    Posttransplant lymphoproliferative disease remains a serious morbidity. Herein we have reported a case of complete regression of a biopsy-proven B-cell lymphoma that occurred in the posttransplant period. A 48-year-old man received a living donor renal transplant for end-stage renal disease due to undetermined etiology. His initial immunosuppression consisted of corticosteroid, mycophenolate mofetil, and cyclosporin. The patient developed severe pneumonia within the first 2 months after transplantation due to Acineotobacter, fungus, and cytomegalovirus infections. He experienced a complete recovery and was discharged for regional follow-up. Four months after discharge, he was referred again because of presence of two nodules on his trunk. A biopsy of the nodules revealed B-cell lymphoma. Cyclosporin was stopped and he was converted to sirolimus. The lesions regressed progressively and completely within 7 weeks. The patient remains well without clinical relapses at 19 months after conversion. Renal functions remained stable. We postulated that the antincoplastic properties of sirolimus may have played an active part in the positive outcome.

    Topics: Biopsy; Cyclosporine; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Regression, Spontaneous; Sirolimus; Skin Neoplasms

2007
Impressive regression of primary liver cancer after treatment with sirolimus.
    Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunosuppressive Agents; Liver Neoplasms; Male; Middle Aged; Neoplasm Regression, Spontaneous; Sirolimus

2005